



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Agreed PIPs for FDCs for the treatment of HIV-1 infection

Introduction for the HIV FDC Expert meeting



Presented by Andrea Ecker on 10 November 2015
Scientific Officer, Paediatric Medicines Office, Human Medicines Research and Development Support Division

An agency of the European Union





General comments

- PDCO reviews FDCs for which the applicant pursues an EU marketing authorisation in adults
- for a new product the legal obligation to complete the PIP is triggered when the product is authorised in adults
- in some instances new active substances seem to be currently developed only in FDCs, not individually
- each PIP is assessed individually on its own merits
- this presentation only includes public information



HIV FDCs with an agreed PIP or waiver

Active Substance (name)	PIP agreed in	PIP completed (completion date)
FTC/RPV/TDF (Eviplera) *	2010	No (2019)
EVG/FTC/TDF/COBI (Stribild) *	2011	No (2020)
LPV/r (oral solution) (Kaletra)	2011	Yes (2015)
LPV/r/3TC	2012	N/A (full waiver)
DTG/ABC/3TC (Triumeq) *	2012	No (2019)
DRV/COBI (Rezolsta)	2013	No (2021)
LPV/3TC/r/AZT *	2013	N/A (full waiver)
RAL/3TC (Dutrebriis)	2014	Yes (2014)
EVG/COBI/FTC/TAF*	2014	No (2017)
ATV/COBI (Evotaz)	2014	No (2019)
FTC/TAF	2015	No (2020)
FTC/TAF/RPV *	2015	No (2021)

HIV FDCs with an agreed PIP or waiver – age range

Active Substance (name)	PIP agreed in	Current paediatric authorisation	Age range of PIP
FTC/RPV/TDF (Eviplera) *	2010	No	> 6 years
EVG/FTC/TDF/COBI (Stribild) *	2011	No	> 6 years
LPV/r (oral solution) (Kaletra)	2011	> 2 yrs	14 days - <2 years
DTG/ABC/3TC (Triumeq) *	2012	> 12 yrs (> 40 kg)	> 2 years
DRV/COBI (Rezolsta)	2013	No	> 3 years
RAL/3TC (Dutrebis)	2014	> 6 yrs (> 30 kg)	> 6 years (> 30 kg)
EVG/COBI/FTC/TAF*	2014	N/A	> 6 years
ATV/COBI (Evotaz)	2014	No	> 3 months
FTC/TAF	2015	N/A	> 4 weeks
FTC/TAF/RPV *	2015	N/A	> 4 weeks

HIV FDCs with an agreed PIP or waiver – age range

Active Substance (name)	PIP agreed in	Current paediatric authorisation	Age range of PIP
FTC/RPV/TDF (Eviplera) *	2010	No	> 6 years
EVG/FTC/TDF/COBI (Stribild) *	2011	No	> 6 years
LPV/r (oral solution) (Kaletra)	2011		
DTG/ABC/3TC (Triumeq) *	2012	> 12	
DRV/COBI (Rezolsta)	2013		
RAL/3TC (Dutrebis)	2014	> 6	
EVG/COBI/FTC/TAF*	2014	N/A	> 6 years
ATV/COBI (Evotaz)	2014	No	> 3 months
FTC/TAF	2015	N/A	> 4 weeks
FTC/TAF/RPV *	2015	N/A	> 4 weeks

**Q1/Q2: Which age range for which product?
Prioritisation criteria?**



Development plans – Quality

Active Substance (name)	Age range of PIP	Agreed quality measure (intended age [yrs])
FTC/RPV/TDF (Eviplera) *	> 6 years	age appropriate film-coated tablet (6-12)
EVG/FTC/TDF/COBI (Stribild) *	> 6 years	age appropriate oral solid dosage form
LPV/r (oral solution) (Kaletra)	14 days - <2 yrs	n/a
DTG/ABC/3TC (Triumeq) *	> 2 years	dispersible tablet
DRV/COBI (Rezolsta)	> 3 years	age-appropriate oral solid dosage form and age-appropriate oral liquid dosage form (3-12)
RAL/3TC (Dutrebriis)	> 6 yrs (>30 kg)	n/a
EVG/COBI/FTC/TAF*	> 6 years	age-appropriate film-coated tablet (6-12)
ATV/COBI (Evotaz)	> 3 months	film-coated tablet (adolescents >40 kg) age-appropriate oral solid dosage form (3 mo-18)
FTC/TAF	> 4 weeks	film-coated tablet (6-12) age-appropriate oral formulation (<6)
FTC/TAF/RPV *	> 4 weeks	film-coated tablet (6-12) age-appropriate oral formulation (<6)

Development plans – Quality

Active Substance (name)	Age range of PIP	Agreed quality measure (intended age [yrs])
FTC/RPV/TDF (Eviplera) *	> 6 years	age appropriate film-coated tablet (6-12)
EVG/FTC/TDF/COBI (Stribild) *	> 6 years	age appropriate film-coated tablet (6-12)
LPV/r (oral solution) (Kaletra)	14 days - <2 yrs	age appropriate oral solution (0-2 yrs)
DTG/ABC/3TC (Triumeq) *	> 6 years	age appropriate film-coated tablet (6-12)
DRV/COBI (Ibalizumab) *	> 6 years	age-appropriate oral formulation (6-12)
RAL/3TC (Dutrebis)	> 6 yrs (>30 kg)	age-appropriate oral solid dosage form (3 mo-18)
EVG/COBI/FTC/TAF*	> 6 years	age-appropriate oral solid dosage form (3 mo-18)
ATV/COBI (Evotam) *	> 6 years	film-coated tablet (adolescents >40 kg)
FTC/TAF	> 6 years	appropriate oral solid dosage form (3 mo-18)
FTC/TAF/RPV *	> 4 weeks	film-coated tablet (6-12) age-appropriate oral formulation (<6)
FTC/TAF/RPV *	> 4 weeks	film-coated tablet (6-12) age-appropriate oral formulation (<6)

Q7: What are desired AAFs?

Q6: use of the adult formulation in adolescents

Q3-5: Feasibility (multiple FDCs in youngest children, diverging from individual active substance dosing, age cut-offs)?



Development plans – Clinical

Active Substance (name)	Age range of PIP	Clinical studies in
FTC/RPV/TDF (Eviplera) *	> 6 years	6-18 yrs
EVG/FTC/TDF/COBI (Stribild) *	> 6 years	6-18 yrs
LPV/r (oral solution) (Kaletra)	14 days - <2 yrs	14 weeks – 37 months
DTG/ABC/3TC (Triumeq) *	> 2 years	2-12 yrs
DRV/COBI (Rezolsta)	> 3 years	3-18 yrs
RAL/3TC (Dutrebriis)	> 6 yrs (>30 kg)	healthy adults only
EVG/COBI/FTC/TAF*	> 6 years	6-18 yrs
ATV/COBI (Evotaz)	> 3 months	healthy adults only
FTC/TAF	> 4 weeks	4 weeks – 18 yrs
FTC/TAF/RPV *	> 4 weeks	healthy adults only



Development plans – Clinical

Active Substance (name)	Age range of PIP	Clinical studies in
FTC/RPV/TDF (Eviplera) *	> 6 years	6-18 yrs
EVG/FTC/TDF/COBI (Stribild) *	> 6 years	
LPV/r (oral solution) (Kaletra)	14 days - <2 yrs	
DTG/ABC/3TC		
DRV/COBI (Ibalanor)		
RAL/3TC (Dolutegravir)		
EVG/COBI/FTC/TAF*	> 6 years	
ATV/COBI (Evotaz)	> 3 months	
FTC/TAF		4 weeks – 18 yrs
FTC/TAF/RPV *		healthy adults only

Q7: Acceptability/palatability data in children?

Q6: Development in adolescents

Q3-5: Feasibility (multiple FDCs in youngest children, diverging from individual active substance dosing, age cut-offs)?